Biotechnology The GBT Foundation Opens 2022 ACCEL Grant Program to Provide Up to $500,000 in Support to Sickle Cell Disease Nonprofit Healthcare Organizations and Institutions June 6, 2022
Biotechnology INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Axsome Therapeutics, Inc. with Losses of $500,000 to Contact the Firm June 6, 2022
Biotechnology Amarin Announces Comprehensive Cost Reduction Plan to Address Market Dynamics in U.S. Business June 6, 2022
Biotechnology ChemoCentryx Reports Safety Results Available from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting June 6, 2022
Biotechnology GBT’s Inclacumab and GBT601 Receive U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for the Treatment of Sickle Cell Disease June 6, 2022
Biotechnology SHAREHOLDER ALERT: Weiss Law Reminds POLY, TREC, BHVN, and SWCH Shareholders About Its Ongoing Investigations June 6, 2022
Search
biotech investors
